We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Roivant Sciences Ltd | NASDAQ:ROIV | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.225 | -1.98% | 11.155 | 11.15 | 11.16 | 11.31 | 10.985 | 11.275 | 3,900,936 | 20:44:59 |
From May 2022 to May 2024
By Colin Kellaher
Roivant Sciences Ltd.'s Dermavant Sciences unit on Tuesday said it received U.S. Food and Drug Administration approval for its Vtama cream 1% for the topical treatment of adults with the chronic inflammatory disease plaque psoriasis.
The pharmaceutical company said Vtama is the first and only FDA-approved steroid-free topical medication in its class, and the first topical novel chemical entity launched for psoriasis in the U.S. in 25 years.
Dermavant said it is ready for a June launch, with product and sample manufacturing runs completed and a fully staffed commercial team.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 24, 2022 06:34 ET (10:34 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Roivant Sciences Chart |
1 Month Roivant Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
